Acquired or secondary thrombophilia.
Strongly Supportive Data |
Active cancer |
Chemotherapy (L-asparaginase, thalidomide, anti-angiogenesis therapy) |
Myeloproliferative disorders |
Heparin-induced thrombocytopenia |
Nephrotic syndrome |
Intravascular coagulation and fibrinolysis/disseminated intravascular coagulation |
Thrombotic thrombocytopenic purpura |
Sickle cell disease |
Oral contraceptives |
Estrogen therapy |
Pregnancy/postpartum state |
Selective estrogen receptor modulator therapy (tamoxifen and raloxifene) |
Antiphospholipid antibodies (lupus anticoagulant, |
anticardiolipin antibody, anti-β2 glycoprotein-1 antibody) |
Paroxysmal nocturnal hemoglobinuria |
Wegener granulomatosis |
Supportive Data |
Inflammatory bowel disease |
Thromboangiitis obliterans (Buerger disease) |
Behçet syndrome |
Varicose veins |
Systemic lupus erythematosus |
Venous vascular anomalies (e.g., Klippel Trenaunay syndrome) |
Progesterone therapy |
Infertility “therapy” |
Hyperhomocysteinemia |
HIV infection |
Dehydration |
Strongly Supportive Data |
Active cancer |
Chemotherapy (L-asparaginase, thalidomide, anti-angiogenesis therapy) |
Myeloproliferative disorders |
Heparin-induced thrombocytopenia |
Nephrotic syndrome |
Intravascular coagulation and fibrinolysis/disseminated intravascular coagulation |
Thrombotic thrombocytopenic purpura |
Sickle cell disease |
Oral contraceptives |
Estrogen therapy |
Pregnancy/postpartum state |
Selective estrogen receptor modulator therapy (tamoxifen and raloxifene) |
Antiphospholipid antibodies (lupus anticoagulant, |
anticardiolipin antibody, anti-β2 glycoprotein-1 antibody) |
Paroxysmal nocturnal hemoglobinuria |
Wegener granulomatosis |
Supportive Data |
Inflammatory bowel disease |
Thromboangiitis obliterans (Buerger disease) |
Behçet syndrome |
Varicose veins |
Systemic lupus erythematosus |
Venous vascular anomalies (e.g., Klippel Trenaunay syndrome) |
Progesterone therapy |
Infertility “therapy” |
Hyperhomocysteinemia |
HIV infection |
Dehydration |